Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Roche/Genentech in race for CAR-T therapy in solid tumors

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Dec 06, 2022 1:17pm

185 Views

Post# 35153857

RE:RE:RE:Roche/Genentech in race for CAR-T therapy in solid tumors

I wasn't aware, until just now, that Coffey wasn't attending the presentation tomorrow & Dr Houra was handling it. With the buzz around tomorrow, the release of formerly embargoed data, there must be good reason he isn't in Boston. The man does like the spotlight. Perhaps negotiations are at the stage where either Parsons or Rigby or both requested his presence? GL for tomorrow all!!!

<< Previous

Bullboard Posts

Next >>

Three micro-cap value stocks trading at peak pessimism